Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4456542
Max Phase: Preclinical
Molecular Formula: C47H54F2N8O13
Molecular Weight: 976.99
Molecule Type: Unknown
Associated Items:
ID: ALA4456542
Max Phase: Preclinical
Molecular Formula: C47H54F2N8O13
Molecular Weight: 976.99
Molecule Type: Unknown
Associated Items:
Canonical SMILES: NC(=O)c1c(-c2ccc(Oc3ccc(F)cc3F)cc2)nn([C@@H]2CCCN(C(=O)OCCOCCOCCOCCOCCOCCNc3cccc4c3C(=O)N(C3CCC(=O)NC3=O)C4=O)C2)c1N
Standard InChI: InChI=1S/C47H54F2N8O13/c48-30-8-12-37(34(49)27-30)70-32-9-6-29(7-10-32)41-40(43(51)59)42(50)57(54-41)31-3-2-15-55(28-31)47(63)69-26-25-68-24-23-67-22-21-66-20-19-65-18-17-64-16-14-52-35-5-1-4-33-39(35)46(62)56(45(33)61)36-11-13-38(58)53-44(36)60/h1,4-10,12,27,31,36,52H,2-3,11,13-26,28,50H2,(H2,51,59)(H,53,58,60)/t31-,36?/m1/s1
Standard InChI Key: XXNGOJVDXDGATG-RACIXVTASA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 976.99 | Molecular Weight (Monoisotopic): 976.3778 | AlogP: 3.67 | #Rotatable Bonds: 25 |
Polar Surface Area: 267.43 | Molecular Species: NEUTRAL | HBA: 17 | HBD: 4 |
#RO5 Violations: 2 | HBA (Lipinski): 21 | HBD (Lipinski): 6 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.59 | CX Basic pKa: 3.10 | CX LogP: 3.04 | CX LogD: 3.04 |
Aromatic Rings: 4 | Heavy Atoms: 70 | QED Weighted: 0.05 | Np Likeness Score: -0.96 |
1. Edmondson SD, Yang B, Fallan C.. (2019) Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges., 29 (13): [PMID:31047748] [10.1016/j.bmcl.2019.04.030] |
Source(1):